If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Lilly has conducted no clinical studies evaluating the safety and efficacy of transitioning patients with either T1DM or T2DM from Novolin to Humulin or vice versa.
Changes that may affect glycemic control and predispose patients to hypoglycemia or hyperglycemia include changes in
method of administration. 1-4
Any change of insulin should be made cautiously and only under medical supervision. The frequency of BG monitoring should be increased. 1-5
Some patients taking Humulin may require a change in dosage from that used with other insulins. If an adjustment is needed, it may occur with the first dose or during the first several weeks or months.3
Enclosed Prescribing Information
Lilly = Eli Lilly and Company
T1DM = type 1 diabetes mellitus
T2DM = type 2 diabetes mellitus
Date of Last Review: July 30, 2018